ACON
Aclarion, Inc.·Healthcare
3.14
0.633%(−0.02)
Market OpenLast Updated: — ET
52W L: $2.3452W H: $12.03
ACON NEWS
zacks.com
May 19
Aclarion (ACON) Upgraded to Buy: Here's Why
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
May 13
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $9.32 per share a year ago.
prismmediawire.com
May 11
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
“Matching the right procedure to the right patient is what moves the field forward” BROOMFIELD, Colo., May 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
globenewswire.com
May 7
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
“Matching the right procedure to the right patient is what moves the field forward” Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early adoption of innovative technologies and high surgical volume The CLARITY randomized clinical trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain BROOMFIELD, Colo., May 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.
prismmediawire.com
May 6
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., May 06, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
globenewswire.com
May 6
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that the compensation committee of Aclarion's board of directors granted Daniel Keefe, the Company's recently-hired Commercial Director, Western U.S., an inducement stock option to purchase an aggregate of 17,000 shares of Aclarion's common stock on May 5, 2026.
